explore -WSS

explore

author：comprehensive 2025-09-27 23:32:09 - browse：5

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： FDA moves to stop vape shops from selling Elf Bar, Esco Bars

hotspot

WSS

How Medicaid coverage policies for immigrants impact new moms

Mindstrong's demise and the future of mental health care

Group opposing PBM reform sets lobbying record

Shingles, which affected Dianne Feinstein, is on the rise

As digital health tech proliferates, a new institute aims to cut through hype

As digital health tech proliferates, a new institute aims to cut through hype

focus

explore

focus

Jerome Adams on the need for new antivirals for Covid

STAT Virtual Event: How to Increase Diversity in Clinical Trials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How the Dana

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Data show record exodus of life scientists from academia

ChatGPT in medicine: STAT answers readers' burning questions

Shingles, which affected Dianne Feinstein, is on the rise

Wildfire smoke exposes gaps in outdoor worker protections

After a drawn out lobbying fight, ARPA

hotspot

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Menendez indictment could see pharma lose a key ally

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

WHO recommends dropping component of many flu vaccines

Sudafed saga points to U.S. issues with evaluating older drugs

Custom gene therapy hints at new path for rare disease treatments

hotspot

leisure time

explore

knowledge